RxDoctor Payments Data

Haleh Khoshreza, MD

Family Medicine · Laguna Hills, CANPI 1386177533

Payments from drug & device makers

$1,038in general payments, 2019–2025

Across 35 payments — averaging $29.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$214
  • Lilly USA, LLC$175
  • Avadel CNS Pharmaceuticals, LLC$92
  • AstraZeneca$60
  • Boehringer Ingelheim$59
  • Takeda Pharmaceuticals U.S.A., Inc.$56
  • plus $382 from 13 others

What the payments were for

  • Food & beverage$1,038100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,038 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$37,249
Medicare patients
180
Services billed
492

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide22$25,904
EliquisApixaban18$20,494
Combivent RespimatIpratropium/Albuterol Sulfate15$8,458
Wixela InhubFluticasone Propion/Salmeterol29$4,261
Incruse ElliptaUmeclidinium Bromide11$3,650
Rosuvastatin Calcium97$1,662
SynthroidLevothyroxine Sodium18$1,455
Atorvastatin Calcium160$1,343
Bupropion XlBupropion Hcl36$1,164
Mirtazapine25$1,163
Levothyroxine Sodium124$1,152
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide12$1,095
Gabapentin75$1,068
Albuterol Sulfate HfaAlbuterol Sulfate38$905
Omeprazole51$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimCombivent Respimat$59$8,45815 claims
GSKIncruse Ellipta$33$3,65011 claims
AbbVieSynthroid$25$1,45518 claims
ANI Pharmaceuticals, Inc.Valsartan$34$32911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in Laguna Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →